Beyond Monotherapy: The Emerging Promise of Finerenone–Empagliflozin Combination in Diabetic Chronic Kidney Disease
International Journal of Contemporary Medicine · 20.07.2026 · 14 (1) · 10-14
DOI: 10.37506/11jtfa32 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Contemporary Medicine, online erschienen am 20.07.2026. Verfasst von Satwik Kuppili und 4 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Diabetic kidney disease (DKD) is a major cause of chronic kidney disease (CKD), end-stage kidney disease, andcardiovascular morbidity among patients with type 2 diabetes mellitus (T2DM). Although glycemic control and renin–angiotensin–aldosterone system (RAAS) blockade remain the cornerstones of management, many patients continueto experience progressive renal dysfunction and adverse cardiovascular outcomes. Recent therapeutic advances havehighlighted the cardiorenal benefits of empagliflozin, a sodium–glucose cotransporter-2 inhibitor (SGLT2i), and finerenone,a selective non-steroidal mineralocorticoid receptor antagonist (ns-MRA). This review evaluates the mechanistic rationale,clinical evidence, and future prospects of combining these agents in patients with CKD and T2DM. A comprehensiveliterature search of PubMed/MEDLINE, Embase, Google Scholar, was conducted, focusing on clinical trials, observationalstudies, and meta-analyses assessing finerenone and empagliflozin individually and in combination. Major outcome trials,including EMPA-KIDNEY, FIDELIO-DKD, FIGARO-DKD, and the pooled FIDELITY analysis, were reviewed, along withdata from the ongoing CONFIDENCE trial. Empagliflozin exerts renoprotective effects primarily through restorationof tubuloglomerular feedback and reduction of intraglomerular pressure, whereas finerenone mitigates inflammation,oxidative stress, and fibrosis by antagonizing mineralocorticoid receptor activation. Their complementary mechanismsprovide a strong biological basis for combination therapy. Clinical evidence demonstrates significant reductions inrenal and cardiovascular events with both agents individually, while subgroup analyses suggest additive benefits anda potentially lower risk of hyperkalemia when finerenone is used alongside an SGLT2i. The ongoing CONFIDENCEtrial is expected to provide prospective evidence regarding the efficacy and safety of early dual-pathway blockade. Inconclusion, the combination of finerenone and empagliflozin represents a biologically plausible strategy for comprehensive cardiorenal protection in diabetic kidney disease. While both agents have independently demonstrated significant renaland cardiovascular benefits in large randomized clinical trials, evidence supporting their combined use currently derivesprimarily from mechanistic rationale and subgroup analyses. Prospective confirmation from dedicated combination trialssuch as CONFIDENCE is awaited.
Zitieren
APA
Kuppili, S., Durve, S., Lella, V., Nimmagadda, R., & Mohammed, N. (2026). Beyond Monotherapy: The Emerging Promise of Finerenone–Empagliflozin Combination in Diabetic Chronic Kidney Disease. International Journal of Contemporary Medicine, 14(1), 10-14. https://doi.org/10.37506/11jtfa32
Vancouver
Kuppili S, Durve S, Lella V, Nimmagadda R, Mohammed N. Beyond Monotherapy: The Emerging Promise of Finerenone–Empagliflozin Combination in Diabetic Chronic Kidney Disease. International Journal of Contemporary Medicine. 2026;14(1):10-14. doi:10.37506/11jtfa32
BibTeX
@article{Kuppili2026,
author = {Kuppili, Satwik and Durve, Shreya and Lella, Vindhya and Nimmagadda, Rithish and Mohammed, Nawazuddin},
title = {Beyond Monotherapy: The Emerging Promise of Finerenone–Empagliflozin Combination in Diabetic Chronic Kidney Disease},
journal = {International Journal of Contemporary Medicine},
year = {2026},
volume = {14},
number = {1},
pages = {10--14},
doi = {10.37506/11jtfa32}
}
EUVIMED